Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO · Real-Time Price · USD
536.19
-2.98 (-0.55%)
At close: Oct 8, 2025, 4:00 PM EDT
535.70
-0.49 (-0.09%)
After-hours: Oct 8, 2025, 4:29 PM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Life Sciences Solutions Revenue
9.83B9.63B
Log In
Log In
Log In
Upgrade
Analytical Instruments Revenue
7.44B7.46B
Log In
Log In
Log In
Upgrade
Specialty Diagnostics Revenue
4.57B4.51B
Log In
Log In
Log In
Upgrade
Laboratory Products and Biopharma Services Revenue
23.31B23.16B
Log In
Log In
Log In
Upgrade
Revenue (Other)
-1.94B-1.88B
Log In
Log In
Log In
Upgrade
Revenue (Total)
43.21B42.88B
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Consumables Revenue
17.86B17.59B
Log In
Log In
Log In
Upgrade
Instruments Revenue
7.29B7.45B
Log In
Log In
Log In
Upgrade
Services Revenue
18.07B17.85B
Log In
Log In
Log In
Upgrade
Revenue (Total)
43.21B42.88B
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
North America Revenue
22.69B22.50B
Log In
Log In
Log In
Upgrade
Europe Revenue
11.03B10.86B
Log In
Log In
Log In
Upgrade
Asia-Pacific Revenue
7.94B7.96B
Log In
Log In
Log In
Upgrade
Other Regions Revenue
1.56B1.56B
Log In
Log In
Log In
Upgrade
Revenue (Other)
-1.00M
Log In
Log In
Log In
Upgrade
Revenue (Total)
43.21B42.88B
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Life Sciences Solutions Operating Income
3.55B3.50B
Log In
Log In
Log In
Upgrade
Analytical Instruments Operating Income
1.84B1.96B
Log In
Log In
Log In
Upgrade
Specialty Diagnostics Operating Income
1.18B1.16B
Log In
Log In
Log In
Upgrade
Laboratory Products and Biopharma Services Operating Income
3.16B3.09B
Log In
Log In
Log In
Upgrade
Operating Income (Other)
-2.32B-2.37B
Log In
Log In
Log In
Upgrade
Operating Income (Total)
7.40B7.34B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
Total Organic Revenue Growth
--
Log In
Log In
Log In
Upgrade
Core Organic Revenue Growth
--
Log In
Log In
Log In
Upgrade
Updated Jul 23, 2025. Data Source: Fiscal.ai.